Sai Life Science Ltd

Sai Life Science Earnings Call Transcript: Key Takeaways

Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.

Sai Life Science Investor Presentation: Key Takeaways

H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.

Sai Life Science Results Update

Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.

Sai Life Science Employee Stock Options

Sai Life Sciences allotted 108,005 ESOP equity shares, taking paid-up capital to Rs.21.26 Crore. No stated consideration means no event value.

Sai Life Science Management Change

Sai Life Sciences appointed three senior management personnel effective 5 November 2026. The appointees include Sidhartha Das as Senior Vice President and Head of Human Resources.

Sai Life Science Q2 FY27 Results: Net Profit ₹98.3 Cr, Up 17.3% YoY

Sai Life Science Ltd reported revenue from operations of ₹658.6 Cr (+22.5% YoY) and net profit of ₹98.3 Cr (+17.3% YoY) for Q2 FY27.

Key figure

Net profit ₹98.3 Cr · +17.3% YoY

Sai Life Science Employee Stock Options

Sai Life Sciences allotted 54,500 equity shares upon the exercise of employee stock options under its ESOP 2008 plan, increasing the total paid-up share capital.

Sai Life Science Other Announcement

Routine quarterly shareholding pattern filing for the quarter ended September 30, 2026, as mandated by SEBI LODR regulations.

Sai Life Science Board Meeting Date

Sai Life Sciences Limited scheduled a board meeting for November 5, 2026. The board will consider unaudited financial results for the quarter ended September 30, 2026.

Sai Life Science Employee Stock Options

Sai Life Sciences Limited has announced the allotment of equity shares under its ESOP scheme. This allotment increases the company's paid-up share capital.

Sai Life Science Employee Stock Options

Sai Life Sciences allotted 24,000 shares upon exercise of ESOP 2008 options at ₹188.90 per share. This issuance increases the company's paid-up equity share capital.

Value

₹0.45 Cr

Sai Life Science Annual General Meeting

Sai Life Sciences summarised proceedings of its 27th AGM held 17 Sep 2026. Shareholders adopted FY25-26 financials and re-appointed MD Krishnamraju Kanumuri.

Sai Life Science Employee Stock Options

Sai Life Sciences Limited allotted 80,600 equity shares under its ESOP/ESPS scheme. This increased the company's total paid-up share capital to ₹21.24 Crore.

Sai Life Science Employee Stock Options

Sai Life Sciences Limited allotted 80,600 equity shares following the exercise of options under its 2008 and 2018 ESOP plans. The total paid-up capital increased to ₹21.24 Crore.

Value

₹0.43 Cr

Sai Life Science Other Announcement

Sai Life Sciences submitted its Business Responsibility and Sustainability Report (BRSR) and ESG Databook for the financial year 2025-26, as required by regulatory norms.

Sai Life Science Annual Report

Sai Life Sciences has filed its Integrated Annual Report for FY 2025-26, including the notice for the 27th AGM scheduled on September 17, 2026.

Sai Life Science Annual General Meeting

Sai Life Sciences Limited scheduled its 27th Annual General Meeting for September 17, 2026. The company set September 10, 2026, as the cut-off date for e-voting.

Sai Life Science Other Announcement

Sai Life Sciences Limited filed its Monitoring Agency Report for the quarter ended 30 June 2026 regarding its IPO proceeds utilization.

Sai Life Science Investor Presentation: Key Takeaways

Sai Life Sciences delivered strong Q1FY27 performance with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY, driven by growth in CRO and CDMO segments.

Call

Guides 20% growth

Sai Life Science Employee Stock Options

Sai Life Sciences Limited allotted 18,700 equity shares under its ESOP/ESPS scheme. This issuance increases the total paid-up share capital of the company.

Sai Life Science Employee Stock Options

Sai Life Sciences allotted 18,700 equity shares under its Employee Stock Option Plan 2008. The exercise of these options realized Rs. 0.35 Crore for the company.

Value

₹0.35 Cr

Sai Life Science Results Update

Sai Life Sciences reported Q1 FY27 revenue of ₹554 crore and PAT of ₹73 crore. It also operationalized a new 100,000 sq. ft. R&D facility.

Sai Life Science Q1 FY27 Results: Net Profit ₹73.3 Cr, Up 21.2% YoY

Sai Life Science Ltd reported revenue from operations of ₹554.3 Cr (+11.7% YoY) and net profit of ₹73.3 Cr (+21.2% YoY) for Q1 FY27.

Key figure

Net profit ₹73.3 Cr · +21.2% YoY

Sai Life Science Other Announcement

Sai Life Sciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per regulatory requirements.

Sai Life Science Employee Stock Options

Sai Life Sciences allotted 8,900 equity shares under its ESOP/ESPS scheme. This increases the total paid-up share capital to 21,22,94,916 shares.

Sai Life Science Employee Stock Options

Sai Life Sciences Limited allotted 8,900 equity shares under its ESOP 2008 scheme. The company realized Rs 0.17 Crore from the exercise of these options.

Value

₹0.17 Cr

Sai Life Science Board Meeting Date

Sai Life Sciences has scheduled a board meeting on 06 August 2026 to consider financial results for Q2 2026. Trading window remains closed till 08 August 2026.

Sai Life Science Earnings Call: Key Takeaways

Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.

Sai Life Science Earnings Call: Key Takeaways

Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.

Sai Life Science Business Update

Sai Life Sciences disclosed certified Key Performance Indicators for fiscal years 2022-2026. The metrics provide detailed visibility into revenue growth, margins, and operational efficiency.